

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Autoimmune disease; inflammation; rheumatoid arthritis (RA)	CC chemokine receptor 1 (CCR1; CD191)	<p><i>In vitro</i> and mouse studies identified CCR1 antagonists that could help treat inflammation in RA and other diseases. Chemical synthesis, SAR and <i>in vitro</i> testing of 4-(4-chlorophenyl)piperidine analogs identified multiple compounds as selective nanomolar antagonists of CCR1. In a human monocyte chemotaxis assay, one of the lead compounds inhibited cell migration with a low nanomolar IC₅₀ value. In mice, the compound showed good bioavailability and pharmacokinetics. Future studies could include testing the lead compound in animal models of RA.</p> <p>CCX354, a small molecule CCR1 antagonist from ChemoCentryx Inc. and GlaxoSmithKline plc, has completed Phase II testing to treat RA.</p> <p>SciBX 5(43); doi:10.1038/scibx.2012.1147 Published online Nov. 1, 2012</p>	Patent and licensing status undisclosed	<p>Cavallaro, C.L. <i>et al.</i> <i>J. Med. Chem.</i>; published online Oct. 17, 2012; doi:10.1021/jm300896d</p> <p>Contact: Cullen L. Cavallaro, Bristol-Myers Squibb Co., Princeton, N.J. e-mail: cullen.cavallaro@bms.com</p>